1. Lockhart SR, Toda M, Benedict K, et al. Endemic and Other Dimorphic Mycoses in The Americas. J Fungi 2021; 7: 151.
2. Thompson GR, 3rd, Le T, Chindamporn A, et al. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical
Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infect Dis 2021; 21:e364-e374.
3. Tirado-Sánchez A, González GM, Bonifaz A. Endemic Mycoses: Epidemiology and Diagnostic Strategies. Expert Rev. Anti Infect Ther 2020; 18: 1105–1117.
4. Almeida-Paes R, Bernardes-Engemann AR, da Silva Motta B, et al. Immunologic Diagnosis of Endemic Mycoses. J Fungi; 2022: 22; 8: 993.
5. Colombo AL, Tobon A, Restrepo A, et al. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol 2011;49: 785–798.
6. Nacher M, Adenis A, Mc DS, et al. Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage. PLoS Negl Trop Dis 2013;7:e2319.
7. Assi M, Martin S, Wheat LJ, et al. Histoplasmosis after solid organ transplant. Clin Infect Dis 2013;57(11):1542–1549.
8. Cottle LE, Gkrania-Klotsas E, Williams HJ, et al. A multinational outbreak of histoplasmosis following a biology field trip in the ugandan rainforest. J Travel Med 2013;20: 83–87.
9. Wheat LJ, Azar MM, Bahr NC, et al. Histoplasmosis. Infect Dis Clin North Am. 2016; 30: 207-227.
10. Arango M, Castaneda E, Agudelo CI, et al. Histoplasmosis: results of the Colombian national survey, 1992-2008. Biomedica 2011;31: 344–356.
11. Pan B, Chen M, Pan W, et al. Histoplasmosis: a new endemic fungal infection in China? Review and analysis of cases. Mycoses 2013;56: 212–221.
12. Jung EJ, Park DW, Choi JW, et al. Chronic cavitary pulmonary histoplasmosis in a non-HIV and immunocompromised patient without overseas travel history. Yonsei Med J 2015;56: 871–874.
13. Lofgren SM, Kirsch EJ, Maro VP, et al. Histoplasmosis among hospitalized febrile patients in northern Tanzania. Trans R Soc Trop Med Hyg 2012;106: 504–507.
14. Rodriguez-Tudela JL, Alastruey-Izquierdo A, Gago S, et al. Burden of serious fungal infections in Spain. Clin Microbiol Infect 2015;21: 183–189.
15. Horwath MC, Fecher RA, Deepe GS Jr. Histoplasma capsulatum, lung infection and immunity. Future Microbiol 2015;10: 967–975.
16. Knox KS, Hage CA. Histoplasmosis. Proc Am Thorac Soc 2010;7: 169–172.
17. Salzer HJF, Burchard G, Cornely OA, et al. Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. Respiration. 2018; 96: 283-301.
18. Hage CA, Knox KS, Wheat LJ. Endemic mycoses: overlooked causes of community acquired pneumonia. Respir Med 2012; 106:769–776.
19. Karimi K, Wheat LJ, Connolly P, et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis 2002; 186:1655–1660.
20. Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011;53: 448–454.
21. Theel ES, Jespersen DJ, Harring J, et al. Evaluation of an Enzyme Immunoassay for Detection of Histoplasma capsulatum Antigen from Urine Specimens. J Clin Microbiol 2013; 51: 3555–3559.
22. Kauffman, C.A. Histoplasmosis: A Clinical and Laboratory Update. Clin. Microbiol Rev 2007; 20: 115–132.
23. Hage CA, Davis TE, Fuller D, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest 2010;137:623–628.
24. Babady NE, Buckwalter SP, Hall L, et al. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from Culture Isolates and Clinical Specimens by Use of Real-Time PCR. J Clin
Microbiol 2011;49: 3204–3208.
25. Linder KA, Kauffman CA, Miceli MH. Blastomycosis: A Review of Mycological and Clinical Aspects. J Fungi 2023; 9: 117.
26. Restrepo A, Baumgardner DJ, Bagagli E, et al. Clues to the presence of pathogenic fungi in certain environments. Med Mycol 2000; 38: 67–77.
27. Baumgardner DJ, Knavel EM, Steber D, et al. Geographic distribution of human blastomycosis cases in Milwaukee, Wisconsin, USA: Association with urban watersheds. Mycopathologia 2006;
161: 275–282.
28. Shelnutt LM, Kaneene JB, Carneito PAM, et al. Prevalence, distribution, and risk factors for canine blastomycosis in Michigan, USA. Med. Mycol 2020; 58: 609–616.
29. Rooney PJ, Klein BS. Sequence elements necessary for transcriptional activation of BAD1 in the yeast phase of Blastomyces dermatitidis. Eukaryot Cell 2004; 3: 785.
30. Wüthrich M, Warner T, Klein BS. IL-12 is required for induction but not maintenance of protective, memory responses to Blastomyces dermatitidis: implications for vaccine development in
immune-deficient hosts. J Immunol 2005; 175:5288.
31. Meece JK, Anderson JL, Gruszka S, et al. Variation in clinical phenotype of human infection among genetic groups of Blastomyces dermatitidis. J Infect Dis 2013; 207:814.
32. Maini R, Ranjha S, Tandan N, et al. Pulmonary blastomycosis: A case series and review of unique radiological findings. Med Mycol Case Rep 2020; 28: 49–54.
33. Schwartz IS, Embil JM, Sharma A, et al. Management and outcomes of acute respiratory distress syndrome caused by blastomycosis. Medicine 2016; 95: e3538.
34. Gray NA, Baddour LM. Cutaneous inoculation blastomycosis. Clin Infect Dis 2002; 34: 44–49.
35. Rammaert B, Gamaletsou MN, Zeller V.et al. Dimorphic fungal osteoarticular infections. Eur J Clin Microbiol Infect Dis 2014; 33: 2131–2140.
36. Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev 2010; 23: 367–381.
37. Connolly P, Hage CA, Bariola JR, et al. Blastomyces dermatitidis antigen detection by quantitative enzyme immunoassay. Clin Vacc Immunol 2012; 19: 53–56.
38. Richer SM, Smedema ML, Durkin MM, et al. Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using Blastomyces dermatitidis surface protein
BAD-1. Clin Vacc Immunol 2014; 21: 143–146.
39. Kauffman CA. Treatment of the midwestern endemic mycoses, blastomycosis and histoplasmosis. Curr Fungal Infect Rep 2017; 11: 67–74.
40. Fisher MC, Koenig GL, White TJ, et al. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of f Coccidioides
immitis. Mycologia 2002; 94: 73–84.
41. Crum NF. Coccidioidomycosis: A Contemporary Review. Infect Dis Ther 2022;11: 713-742.
42. Williams SL, Chiller T. Update on the Epidemiology, Diagnosis, and Treatment of Coccidioidomycosis. J Fungi 2022; 8: 666.
43. Martı´n-Da´vila P, Fortu´n J, Lo´pez-Ve´lez R. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev. 2008;21: 60–96.
44. Donovan FM, Shubitz L, Powell D, et al. Early events in coccidioidomycosis. Clin Microbiol Rev 2019;33:e00112- e119.
45. Kirkland TN, Fierer J. Coccidioides immitis and posadasii; A review of their biology, genomics, pathogenesis, and host immunity. Virulence 2018;9: 1426-1435.
46-. Thompson GR, Bays DJ, Johnson SM, etal. Serum (1,3)-b-dglucan measurement in coccidioidomycosis. J Clin Microbiol 2012;50: 3060–3062.
47. Teixeira MM, Theodoro RC, Nino-Vega G, et al. Paracoccidioides species complex: ecology, phylogeny, sexual reproduction, and virulence. PLoS Pathog 2014; 10:e1004397.
48. Hahn RC, Hagen F, Mendes RP, et al. Paracoccidioidomycosis: Current Status and Future Trends. Clin Microbiol Rev 2022;35:e0023321.
49. Moreto TC, Marques MEA, de Oliveira MLSC, et al. Accuracy of routine diagnostic tests used in paracoccidioidomycosis patients at a university hospital. Trans R Soc Trop Med Hyg 2011;
105:473–478.
50. Menezes VM, Soares BG, Fontes CJ. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev 2006; 2:CD004967